NCT06760156 is a Phase 2 clinical trial of Tafasitamab in Large B-cell Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT06760156?

NCT06760156 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT06760156?

Interventions in NCT06760156: Tafasitamab, Lenalidomide.

What condition does NCT06760156 study?

NCT06760156 studies Large B-cell Lymphoma.

Is NCT06760156 still recruiting?

NCT06760156 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06760156

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma After Axicabtagene Ciloleucel

Recruiting now Phase 2 Last updated 30 March 2026

What this trial tests

Phase 2 trial testing Tafasitamab in Large B-cell Lymphoma in 28 participants. Currently enrolling.

Timeline

19 March 2025

Primary endpoint
1 January 2027

1 January 2028

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	19 March 2025
Primary completion	1 January 2027
Estimated completion	1 January 2028
Sites	1 location across United States

Drugs / interventions tested

Tafasitamab — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Large B-cell Lymphoma — all drugs for Large B-cell Lymphoma →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete Response Rate (CRR)
Time frame: Up to 3 months
Complete Response Rate (CRR) is defined as the proportion of patients with a Complete Response (CR)

Sponsor's own description

The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tafasitamab

Trials testing the same drug.

NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07030699 — A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma · Phase 2 · withdrawn
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06434363 — Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di · Phase 1, PHASE2 · recruiting
NCT06029309 — Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other recruiting trials for Large B-cell Lymphoma

Currently open trials in the same condition.

NCT07052305 — NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Sub · Phase 1 · recruiting
NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT06994169 — Glofitamab in Real Life · recruiting
NCT07215585 — AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL · Phase 3 · recruiting
NCT07240194 — The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refra · Phase 2 · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06760156 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06760156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing